Robert C Doebele

List of Publications by Year
in descending order

164	23,250	17440 63	8396 147
papers	citations	h-index	g-index

170	170	170	20896
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Efficacy of Larotrectinib inTRKFusionâ€“Positive Cancers in Adults and Children. New England Journal of Medicine, 2018, 378, 731-739.	27.0	2,036
2	Crizotinib in ROS1-Rearranged Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2014, 371, 1963-1971.	27.0	1,656
3	Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1â€“2 trials. Lancet Oncology, The, 2020, 21, 271-282.	10.7	1,034
4	Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2012, 18, 1472-1482.	7.0	1,018
5	Nonâ€“Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 504-535.	4.9	994
6	Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Nonâ€“Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. Journal of Clinical Oncology, 2019, 37, 1558-1565.	1.6	882
7	Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncology, The, 2016, 17, 1672-1682.	10.7	865
8	Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncology, The, 2011, 12, 1004-1012.	10.7	847
9	Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discovery, 2017, 7, 400-409.	9.4	647
10	Rociletinib in EGFR-Mutated Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2015, 372, 1700-1709.	27.0	615
11	Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1807-1814.	1.1	585
12	Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nature Medicine, 2013, 19, 1469-1472.	30.7	526
13	TRKing Down an Old Oncogene in a New Era of Targeted Therapy. Cancer Discovery, 2015, 5, 25-34.	9.4	509
14	Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nature Genetics, 2017, 49, 1693-1704.	21.4	423
15	Identifying and Targeting ROS1 Gene Fusions in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2012, 18, 4570-4579.	7.0	405
16	Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing. Cell, 2020, 182, 1232-1251.e22.	28.9	371
17	Mechanisms and clinical activity of an EGFR and HER2 exon 20â€“selective kinase inhibitor in nonâ€“small cell lung cancer. Nature Medicine, 2018, 24, 638-646.	30.7	351
18	Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nature Reviews Clinical Oncology, 2019, 16, 341-355.	27.6	347

#	Article	IF	Citations
19	An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101. Cancer Discovery, 2015, 5, 1049-1057.	9.4	343
20	Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment. Clinical Cancer Research, 2010, 16, 5581-5590.	7.0	325
21	Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. Cancer Discovery, 2018, 8, 1227-1236.	9.4	321
22	Molecular Pathways: ROS1 Fusion Proteins in Cancer. Clinical Cancer Research, 2013, 19, 4040-4045.	7.0	310
23	Acral Lentiginous Melanoma Harboring a ROS1 Gene Fusion With Clinical Response to Entrectinib. JCO Precision Oncology, 2017, 1, 1-7.	3.0	309
24	Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1â€“2 trials. Lancet Oncology, The, 2020, 21, 261-270.	10.7	303
25	Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. Journal of Clinical Oncology, 2017, 35, 1403-1410.	1.6	277
26	Oncogene status predicts patterns of metastatic spread in treatmentâ€naive nonsmall cell lung cancer. Cancer, 2012, 118, 4502-4511.	4.1	247
27	RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALKâ€“positive lung cancer. Nature Medicine, 2015, 21, 1038-1047.	30.7	245
28	Phase II Trial of Stereotactic Body Radiation Therapy Combined With Erlotinib for Patients With Limited but Progressive Metastatic Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2014, 32, 3824-3830.	1.6	244
29	Treating ALK-positive lung cancerâ€”early successes and future challenges. Nature Reviews Clinical Oncology, 2012, 9, 268-277.	27.6	224
30	Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncology, The, 2021, 22, 959-969.	10.7	222
31	Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed. Journal of Thoracic Oncology, 2011, 6, 774-780.	1.1	221
32	Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Nonâ€“Small Cell Lung Cancer. Cancer Discovery, 2013, 3, 430-443.	9.4	203
33	Stereotactic Radiation Therapy can Safely and Durably Control Sites of Extra-Central Nervous System Oligoprogressive Disease in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients Receiving Crizotinib. International Journal of Radiation Oncology Biology Physics, 2014, 88, 892-898.	0.8	182
34	Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Nonâ€“small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 3334-3347.	7.0	182
35	HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib. Annals of Oncology, 2019, 30, 447-455.	1.2	151
36	A framework for understanding and targeting residual disease in oncogene-driven solid cancers. Nature Medicine, 2016, 22, 472-478.	30.7	145

#	Article	IF	Citations
37	Identifying the Appropriate FISH Criteria for Defining MET Copy Numberâ€“Driven Lung Adenocarcinoma through Oncogene Overlap Analysis. Journal of Thoracic Oncology, 2016, 11, 1293-1304.	1.1	143
38	Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 2758-2770.	7.0	143
39	Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 1818-1831.	1.1	133
40	Rapidly Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in NSCLC Cell Lines through De-Repression of FGFR2 and FGFR3 Expression. PLoS ONE, 2010, 5, e14117.	2.5	130
41	Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples. Journal of Thoracic Oncology, 2018, 13, 1474-1482.	1.1	130
42	Molecularly Targeted Therapies in Nonâ€“Small-Cell Lung Cancer Annual Update 2014. Journal of Thoracic Oncology, 2015, 10, S1-S63.	1.1	119
43	The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Nonâ€“Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib. Journal of Thoracic Oncology, 2018, 13, 1717-1726.	1.1	119
44	Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer. PLoS ONE, 2013, 8, e82236.	2.5	116
45	Clinicopathologic Features of Nonâ€“Small-Cell Lung Cancer Harboring an NTRK Gene Fusion. JCO Precision Oncology, 2018, 2018, 1-12.	3.0	112
46	Determination of the HLA-DM Interaction Site on HLA-DR Molecules. Immunity, 2000, 13, 517-527.	14.3	110
47	Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. Annals of Oncology, 2019, 30, 325-331.	1.2	110
48	Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 691-700.	1.1	108
49	ROS1 and ALK Fusions in Colorectal Cancer, with Evidence of Intratumoral Heterogeneity for Molecular Drivers. Molecular Cancer Research, 2014, 12, 111-118.	3.4	104
50	Dramatic Response to Crizotinib in a Patient With Lung Cancer Positive for an HLA-DRB1-MET Gene Fusion. JCO Precision Oncology, 2017, 2017, 1-6.	3.0	103
51	Interaction of HLA-DR with an Acidic Face of HLA-DM Disrupts Sequence-Dependent Interactions with Peptides. Immunity, 2003, 19, 183-192.	14.3	93
52	Accessory molecules for MHC class II peptide loading. Current Opinion in Immunology, 2000, 12, 99-106.	5.5	90
53	Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement,ALKsignal copy number, and response to crizotinib therapy inALKfluorescence in situ hybridization-positive nonsmall cell lung cancer. Cancer, 2012, 118, 4486-4494.	4.1	88
54	A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105. Cancer Discovery, 2019, 9, 384-395.	9.4	88

#	Article	IF	Citations
55	Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases. Journal of Pharmacology and Experimental Therapeutics, 2018, 364, 494-503.	2.5	85
56	Rapidâ€onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer, 2012, 118, 5302-5309.	4.1	84
57	PrlA and PrlG suppressors reduce the requirement for signal sequence recognition. Journal of Bacteriology, 1994, 176, 5607-5614.	2.2	80
58	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or MetastaticROS1Fusionâ€“Positive Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2021, 39, 1253-1263.	1.6	74
59	Activation of RAS family members confers resistance to ROS1 targeting drugs. Oncotarget, 2015, 6, 5182-5194.	1.8	72
60	An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 1273-1281.	1.1	71
61	Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy. Annals of Oncology, 2017, 28, 2707-2714.	1.2	70
62	A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer. Annals of Oncology, 2012, 23, 2094-2102.	1.2	68
63	Diagnostic assays for identification of anaplastic lymphoma kinaseâ€positive nonâ€“small cell lung cancer. Cancer, 2013, 119, 1467-1477.	4.1	68
64	Do More With Less: Tips and Techniques for Maximizing Small Biopsy and Cytology Specimens for Molecular and Ancillary Testing: The University of Colorado Experience. Archives of Pathology and Laboratory Medicine, 2016, 140, 1206-1220.	2.5	68
65	Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling. Molecular Cancer Therapeutics, 2017, 16, 1623-1633.	4.1	66
66	EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases. Cancer Research, 2017, 77, 3551-3563.	0.9	65
67	Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations. Clinical Cancer Research, 2019, 25, 5832-5842.	7.0	64
68	Targeted Therapies in Non-Small Cell Lung Cancer: Emerging Oncogene Targets Following the Success of Epidermal Growth Factor Receptor. Seminars in Oncology, 2014, 41, 110-125.	2.2	60
69	Anthrax Edema Toxin Inhibits Endothelial Cell Chemotaxis via Epac and Rap1. Journal of Biological Chemistry, 2007, 282, 19781-19787.	3.4	59
70	New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer. Lung Cancer, 2010, 69, 1-12.	2.0	59
71	Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins. Cancer Research, 2019, 79, 546-556.	0.9	59
72	Phase 2, randomized, openâ€label study of ramucirumab in combination with firstâ€line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic nonâ€“small cell lung cancer. Cancer, 2015, 121, 883-892.	4.1	58

#	Article	IF	Citations
73	ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events. Journal of Thoracic Oncology, 2019, 14, 596-605.	1.1	56
74	Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes. Clinical Cancer Research, 2021, 27, 1463-1475.	7.0	52
75	A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 419-426.	1.1	48
76	Excellent Outcomes with Radiosurgery for MultipleÂBrain Metastases in ALK and EGFR DrivenÂNonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 715-720.	1.1	48
77	A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer. Frontiers in Oncology, 2019, 9, 195.	2.8	48
78	Adding to the Mix: Fibroblast Growth Factor and Platelet-Derived Growth Factor Receptor Pathways as Targets in Non â€“ small Cell Lung Cancer. Current Cancer Drug Targets, 2012, 12, 107-123.	1.6	47
79	Native and rearranged ALK copy number and rearranged cell count in nonâ€“small cell lung cancer. Cancer, 2013, 119, 3968-3975.	4.1	47
80	A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2014, 9, 1532-1539.	1.1	47
81	Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. Cancer, 2013, 119, 2383-2390.	4.1	45
82	A novel interplay between Epac/Rap1 and mitogen-activated protein kinase kinase 5/extracellular signal-regulated kinase 5 (MEK5/ERK5) regulates thrombospondin to control angiogenesis. Blood, 2009, 114, 4592-4600.	1.4	43
83	ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms. Molecular Cancer Therapeutics, 2018, 17, 222-231.	4.1	38
84	Novel Fc gamma receptor I family gene products in human mononuclear cells.. Journal of Clinical Investigation, 1992, 90, 2102-2109.	8.2	38
85	Management of Brain Metastases in ALK-Positive Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2016, 34, 2814-2819.	1.6	37
86	Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer. Oncologist, 2019, 24, 1095-1102.	3.7	37
87	Clinicopathologic Features and Response to Therapy ofNRG1Fusionâ€“Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. Journal of Clinical Oncology, 2021, 39, 2791-2802.	1.6	32
88	Novel glycosylation of HLA-DRalpha disrupts antigen presentation without altering endosomal localization. Journal of Immunology, 1998, 160, 4289-97.	0.8	31
89	Point Mutations in or Near the Antigen-Binding Groove of HLA-DR3 Implicate Class II-Associated Invariant Chain Peptide Affinity as a Constraint on MHC Class II Polymorphism. Journal of Immunology, 2003, 170, 4683-4692.	0.8	28
90	Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms. , 2020, 8, e000441.		28

#	Article	IF	Citations
91	Acquired Resistance Is Oncogene and Drug Agnostic. Cancer Cell, 2019, 36, 347-349.	16.8	26
92	Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2020, 21, e191-e204.	2.6	26
93	Clinical Benefit From Pemetrexed Before and After Crizotinib Exposure and From Crizotinib Before and After Pemetrexed Exposure in Patients With Anaplastic Lymphoma Kinase-Positive Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2013, 14, 636-643.	2.6	25
94	ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer. Oncotarget, 2018, 9, 8823-8835.	1.8	24
95	Aberrant intermolecular disulfide bonding in a mutant HLA-DM molecule: implications for assembly, maturation, and function. Journal of Immunology, 1998, 160, 734-43.	0.8	23
96	Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions. Oncotarget, 2017, 8, 11114-11126.	1.8	22
97	Preliminary Clinical and Molecular Analysis Results From a Single-Arm Phase 2 Trial of Brigatinib in Patients With Disease Progression After Next-Generation ALK Tyrosine Kinase Inhibitors in Advanced ALK+ NSCLC. Journal of Thoracic Oncology, 2021, 16, 156-161.	1.1	22
98	A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer. Npj Precision Oncology, 2021, 5, 41.	5.4	22
99	Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. Journal of Thoracic Oncology, 2018, 13, 134-138.	1.1	21
100	Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status. Lung Cancer, 2016, 96, 27-32.	2.0	20
101	A Novel Interplay between Rap1 and PKA Regulates Induction of Angiogenesis in Prostate Cancer. PLoS ONE, 2012, 7, e49893.	2.5	20
102	Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma. Cancer Chemotherapy and Pharmacology, 2013, 71, 307-319.	2.3	18
103	Abstract CT007: Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naÃ¯ve patients with advanced solid tumors harboring gene rearrangements: Updated phase I results. Cancer Research, 2016, 76, CT007-CT007.	0.9	17
104	Neoadjuvant Oncogene-Targeted Therapy in Early Stage Nonâ€“Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance. Clinical Lung Cancer, 2016, 17, 466-469.	2.6	16
105	Targeted therapies for ROS1-rearranged non-small cell lung cancer. Drugs of Today, 2019, 55, 641.	1.1	16
106	Activity of <scp>tarloxotinibâ€Ł</scp> in cells with <scp>EGFR</scp> exonâ€20 insertion mutations and mechanisms of acquired resistance. Thoracic Cancer, 2021, 12, 1511-1516.	1.9	15
107	ALK gene rearrangements in unselected caucasians with non-small cell lung carcinoma (NSCLC).. Journal of Clinical Oncology, 2010, 28, 10533-10533.	1.6	15
108	Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusionâ€“Positive NSCLC. JTO Clinical and Research Reports, 2022, 3, 100332.	1.1	15

#	Article	IF	Citations
109	Genetic Testing for Lung Cancer: Reflex Versus Clinical Selection. Journal of Clinical Oncology, 2011, 29, 1943-1945.	1.6	14
110	Abstract CT060: STARTRK-2: A global phase 2, open-label, basket study of entrectinib in patients with locally advanced or metastatic solid tumors harboring TRK, ROS1, or ALK gene fusions. Cancer Research, 2017, 77, CT060-CT060.	0.9	13
111	Acquired Resistance to Targeted Therapies in Advanced Non-Small Cell Lung Cancer: New Strategies and New Agents. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e272-e278.	3.8	12
112	The Minority Report: Targeting the Rare Oncogenes in NSCLC. Current Treatment Options in Oncology, 2014, 15, 644-657.	3.0	12
113	Development of syngeneic murine cell lines for use in immunocompetent orthotopic lung cancer models. Cancer Cell International, 2020, 20, 417.	4.1	12
114	Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data inROS1+ NSCLC. Journal of Comparative Effectiveness Research, 2021, 10, 1271-1282.	1.4	12
115	Acquired Resistance to Targeted Therapies in Advanced Non-Small Cell Lung Cancer: New Strategies and New Agents. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e272-e278.	3.8	12
116	Duration of Targeted Therapy in Patients With Advanced Nonâ€“small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis. Clinical Lung Cancer, 2020, 21, 545-552.e1.	2.6	11
117	Targeting ALK, ROS1, and BRAF Kinases. Journal of Thoracic Oncology, 2012, 7, S375-S376.	1.1	10
118	Abstract 4529: Pharmacokinetics (PK) of LOXO-101 during the first-in-human Phase I study in patients with advanced solid tumors: Interim update. Cancer Research, 2015, 75, 4529-4529.	0.9	10
119	Crizotinib for the treatment of patients with advanced non-small cell lung cancer. Drugs of Today, 2012, 48, 271.	1.1	10
120	Preâ€•and postâ€treatment bloodâ€based genomic landscape of patients with ROS1 or NTRK fusionâ€positive solid tumours treated with entrectinib. Molecular Oncology, 2022, 16, 2000-2014.	4.6	10
121	High dose acetaminophen inhibits STAT3 and has free radical independent anti-cancer stem cell activity. Neoplasia, 2021, 23, 348-359.	5.3	9
122	The Evolution of Tumor Classification: A Role for Genomics?. Cancer Cell, 2013, 24, 693-694.	16.8	8
123	EGFR Exon 19 Deletion Mutations and Systemic/Central Nervous System Miliary Metastasis: Clinical Correlations and Response to Therapy. Clinical Lung Cancer, 2014, 15, 387-389.	2.6	7
124	The Democratization of the Oncogene. Cancer Discovery, 2014, 4, 870-872.	9.4	7
125	Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study. Translational Lung Cancer Research, 2021, 10, 3659-3670.	2.8	7
126	Phase I open-label study of cediranib plus etoposide (E) and cisplatin (P) as first-line therapy for patients (pts) with small cell lung cancer (SCLC) or lung neuroendocrine cancer (NEC).. Journal of Clinical Oncology, 2010, 28, 7050-7050.	1.6	7

#	Article	IF	Citations
127	GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers. Communications Biology, 2022, 5, 373.	4.4	7
128	Biomarkers Are Here to Stay for Clinical Research and Standard Care. Journal of Thoracic Oncology, 2010, 5, 1113-1115.	1.1	6
129	Oncogenic Fusions Involving Exon 19 of ALK. Journal of Thoracic Oncology, 2012, 7, e44.	1.1	6
130	Time to shift the burden of proof for oncogene-positive cancer?. Nature Reviews Clinical Oncology, 2013, 10, 492-493.	27.6	6
131	Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR. Journal of Thoracic Oncology, 2013, 8, e83-e84.	1.1	6
132	A Nice Problem to Have: When ALK Inhibitor Therapy Works Better Than Expected. Journal of Thoracic Oncology, 2014, 9, 433-435.	1.1	6
133	Larotrectinib Is Highly Active in Patients With Advanced Recurrent TRK Fusion Thyroid (TC) and Salivary Gland Cancers (SGC). International Journal of Radiation Oncology Biology Physics, 2018, 100, 1318.	0.8	6
134	HLA Class I Binding of Mutant EGFR Peptides in NSCLC Is Associated With Improved Survival. Journal of Thoracic Oncology, 2021, 16, 104-112.	1.1	6
135	Novel Human-Derived RET Fusion NSCLC Cell Lines Have Heterogeneous Responses to RET Inhibitors and Differential Regulation of Downstream Signaling. Molecular Pharmacology, 2021, 99, 435-447.	2.3	6
136	Reply to M.C. Garassino et al. Journal of Clinical Oncology, 2011, 29, 3837-3838.	1.6	5
137	Re-examination of Maintenance Therapy in Non-Small Cell Lung Cancer with the Advent of New Anti-cancer Agents. Drugs, 2013, 73, 517-532.	10.9	5
138	Dramatic Response to Lorlatinib in a Patient With CD74-ROS1-Positive Lung Adenocarcinoma With Acquired F2004V Mutation. JCO Precision Oncology, 2019, 3, 1-6.	3.0	5
139	Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC. Npj Precision Oncology, 2021, 5, 91.	5.4	5
140	Milademetan is a highly potent MDM2 inhibitor in Merkel cell carcinoma. JCI Insight, 2022, 7, .	5.0	5
141	Granulomatosis with polyangiitis in a patient treated with dabrafenib and trametinib for BRAF V600E positive lung adenocarcinoma. BMC Cancer, 2020, 20, 177.	2.6	4
142	P2.06-007 A Phase 1/2 Trial of the Oral EGFR/HER2 Inhibitor AP32788 in Nonâ€“Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2017, 12, S1072-S1073.	1.1	3
143	First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Nonâ€“Small-cell Lung Cancer With Different Prognostic Significance. Clinical Lung Cancer, 2018, 19, 531-543.	2.6	3
144	Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 510.	2.8	3

#	Article	IF	Citations
145	A time to test, a time to treat. Journal of Thoracic Disease, 2012, 4, 223-5.	1.4	3
146	Pharmacodynamic Studies in Early Phase Drug Development. , 2011, , 215-256.		2
147	Abstract LB-449: KRAS mutation and amplification status predicts sensitivity to antifolate therapies in non-small-cell lung cancer. , 2012, , .		2
148	Abstract LB-118: Identification of TRKA and TRKB kinase domain mutations that induce resistance to a pan-TRK inhibitor. , 2016, , .		2
149	Abstract 5233: Evolution of therapy resistance through acquired KRAS amplification in ROS1 fusion KRAS G12C double positive NSCLC. Cancer Research, 2022, 82, 5233-5233.	0.9	2
150	MA16.03 Global RET Registry (GLORY): Activity of RET-Directed Targeted Therapies in RET-Rearranged Lung Cancers. Journal of Thoracic Oncology, 2017, 12, S435-S436.	1.1	1
151	Abstract 3878: Bach1 promotes liver metastasis of colorectal cancer cells by regulating c-Myc and SOX4.. , 2013, , .		1
152	Final Results of a Phase 2, Open-Label Study of Ramucirumab (IMC-1121B; RAM), an IGG1 MAB Targeting Vegfr-2, with Paclitaxel and Carboplatin as First-Line Therapy in Patients (PTS) with Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) (NCT00735696). Annals of Oncology, 2012, 23, ix422-ix423.	1.2	0
153	Rearranging Detection of Gene Rearrangements. Journal of Thoracic Oncology, 2015, 10, 1129-1130.	1.1	0
154	PS01.68: Heterogeneous Clinical Syndromes Existing Within Patients with Stage IV KRAS Mutant Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2016, 11, S313.	1.1	0
155	P1.02-057 Clinical Utility of ctDNA for Detecting ALK Fusions and Resistance Events in NSCLC: Analysis of a Laboratory Cohort. Journal of Thoracic Oncology, 2017, 12, S522.	1.1	0
156	Targeting Residual Disease in Oncogene-Driven NSCLC. Journal of Thoracic Oncology, 2017, 12, S1546.	1.1	0
157	Reply to J.K. Molitoris et al. Journal of Clinical Oncology, 2017, 35, 810-811.	1.6	0
158	The importance of the initial response to cancer treatment in predicting longer overall survival. Expert Review of Clinical Pharmacology, 2018, 11, 109-111.	3.1	0
159	Abstract 812: Lack of intra-tumoral heterogeneity in lung adenocarcinoma supports gene fusions involving ALK as early clonal events. , 2010, , .		0
160	Abstract 3467: A novel interplay between Rap1, Epac and PKA regulates induction of angiogenesis. , 2011, , .		0
161	Abstract 5594: ALK-driven lung cancer: Potential therapeutic strategies for treatment and prevention of drug resistance. , 2012, , .		0
162	Abstract 894: Targeting ROS1 receptor tyrosine kinase gene fusions in non-small cell lung cancer. , 2012, , .		0

#	Article	IF	Citations
163	Abstract IA41: A new TRacK in lung cancer: NTRK1 gene fusions as a therapeutic target.. Clinical Cancer Research, 2014, 20, IA41-IA41.	7.0	0
164	Abstract 5255: EGFR is a conspiring kinase in gene fusion positive lung cancer. , 2014, , .		0